Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 09/20 11:36:11 am
82.58 EUR   +0.40%
09/19 SANOFI : and Regeneron Announce Positive Study Results for Dupixent ..
09/18 SANOFI : Disclosure of trading in own shares
09/18 SANOFI : Disclosure of trading in own shares
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/19 SANOFI : and Regeneron Announce Positive Study Results for Dupixent in Patients ..
09/18 SANOFI : Disclosure of trading in own shares
09/18 SANOFI : Disclosure of trading in own shares
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/18 SANOFI : and Regeneron Announce Positive Study Results for Dupixent (dupilumab) ..
09/16 SANOFI : Aventis Ukraine seeks to file claim to international court to protect i..
09/16 SANOFI : and Regeneron Announce Positive Study Results for Dupixent® (dupilumab)..
09/16 SANOFI : Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dup..
09/16 SANOFI : and Regeneron Announce Positive Study Results for Dupixent® (dupilumab)..
09/15 KERYX BIOPHARMACEUTICALS : Announces Changes to its Board of Directors
More news
News from SeekingAlpha
09/19 YOUR DAILY PHARMA SCOOP : Nabriva's Further Potential, Allergan's IP Gimmick, Su..
09/18 Sanofi (SNY) Presents At Bank of America Merrill Lynch 2017 Global Healthcare..
09/18 Regeneron and Sanofi's Dupixent shows positive effect in dermatitis patients ..
09/18 NOVARTIS : The Value Creator
09/16 Stocks to watch next week
Financials (€)
Sales 2017 36 307 M
EBIT 2017 9 642 M
Net income 2017 7 849 M
Debt 2017 5 108 M
Yield 2017 3,70%
P/E ratio 2017 13,36
P/E ratio 2018 17,39
EV / Sales 2017 3,00x
EV / Sales 2018 2,91x
Capitalization 104 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,2 €
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI5.81%124 759
JOHNSON & JOHNSON16.70%363 360
NOVARTIS11.20%223 865
ROCHE HOLDING LTD.4.56%219 130
PFIZER9.45%211 705
MERCK AND COMPANY12.38%179 978